Amylyx Pharmaceuticals, Inc.

AMLX

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001193125-26-091443
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: Klee Justin B. (CEO)

Summary

Type

Sell

Net shares

-29,282

% of shares

-0.87%

Amount (USD)

$423,760

Insider confidence score

42.5 out of 100

Positive

  • Tax withholding obligation

Negative

  • Moderate tax withholding sell (≥0.5% of shares)
  • Large sell amount ($250K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-29,282.0

Price per Share

$14.47

Amount (USD)

$423,760.32

Acquired/Disposed

Disposed

Shares Owned Before

3,363,898.0

Shares Owned After

3,334,616.0

Filing's footnotes

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.360. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.